July 12, 2017 / 5:09 AM / 13 days ago

BRIEF-Abivax announces data on anti-inflammatory effects of ABX464

1 Min Read

July 12 (Reuters) - ABIVAX SA:

* NEW EXPERIMENTAL DATA ON ANTI-INFLAMMATORY EFFECTS OF ABX464, ABIVAX’S FIRST-IN-CLASS DRUG CANDIDATE TO ACHIEVE FUNCTIONAL CURE IN HIV-PATIENTS, PUBLISHED IN NATURE SCIENTIFIC REPORTS

* ‍ABX464 SHOWN TO DAMPEN INTESTINAL INFLAMMATION BY TRIGGERING IL-22 PRODUCTION IN ACTIVATED MACROPHAGES​

* ‍PROOF-OF-CONCEPT PHASE 2 TRIAL IN IBD (ULCERATIVE COLITIS) PLANNED TO BEGIN IN 2H 2017​

* RESULTING ANTI-INFLAMMATORY EFFECT PROTECTED MICE FROM A LETHAL MODEL OF COLITIS, WITH FULL PRESERVATION OF BOWEL STRUCTURE SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below